Anuradha (Bapsi) Chakravarthy, M.D.
Professor of Radiation Oncology
Patient Contact Information:
The Vanderbilt Clinic (TVC) - Preston Research Building
Department of Radiation Oncology, B1003
1301 22nd Ave. South
Nashville, TN 37323-5671
Further Information: 1-800-811-8480
Vanderbilt-Ingram Cancer Center Radiation Oncology
22nd at Pierce Avenue, B1034
Nashville, TN 37232-5671
Healthcare Provider Contact Information:
Dr. Anuradha (Bapsi) Chakravarthy, known better to her patients and colleagues as Bapsi Chak, is a member of the faculty and Residency Director in the Department of Radiation Oncology at Vanderbilt University Medical Center.
Dr. Chak received her Doctor of Medicine degree from the George Washington University, Washington, D.C. Following a residency in Internal Medicine at the Mayo Clinic she completed a fellowship in Medical Oncology at the University of Maryland and Radiation Oncology at the Johns Hopkins University. She is board certified in both radiation oncology and medical oncology. She has served on several university committees including the Scientific Review Committee, the Institutional Review Board, the Committee on Continuing Medical Education, and the Data Safety and Monitoring Board.
Dr. Chak's clinical interests involve treating malignancies of the breast and gastrointestinal tract (esophageal, pancreas, gastric, colorectal, and anal). Her research interests involve the development of markers to predict therapeutic response. Currently we treat many patients empirically with drugs that may benefit the population as a whole but not necessarily the individual. Using new technologies to study analyze thousands of genes and proteins simultaneously from tumors, Dr. Chak hopes to identify molecular patterns that will predict an individual's response to specific agents. Dr. Chak works closely with basic scientists to help bring ideas developed in the laboratory directly to patient care. She is a co-investigator with Dr. Jennifer Pietenpol on a project in the breast SPORE that examines predictive markers of clinical response to docetaxel therapy in locally advanced breast cancer. She is also co-investigator with Dr. R.D. Beauchamp on a project in the GI SPORE that involves molecular profiling of rectal cancers to evaluate the role of COX-2 inhibition. In addition to molecular profiling to predict therapeutic outcome, Dr. Chak also works with imaging scientists to determine whether non-invasive tools such as imaging breast cancers can be used to predict therapeutic outcome. Dr. Chak's research is funded by several grants from the National Institutes of Health and from pharmaceutical companies.
Clincial Research Description:
Dr. Chak's primary clinical interests are in Breast and Gastrointestinal Malignancies. Her research interests include the development of novel ways to combine radiation with Radiosensitizing Chemotherapy. Patients interested in participating in studies looking at better ways to combine Chemotherapy and Radiation should contact: Ms. Teresa Knoop 1-800-811-8480 . Chakravarthy A. A pilot study of Molecular-Based Therapy utilizing neoadjuvant paclitaxel and concurent radiation in Stage II/III breast cancer, Discovery Grant, VUMC Chakravarthy A. A pilot study of neoadjuvant paclitaxel and concurrent radiation with correlative molecular studies in Stage II/III breast cancer, Clinical Research Grant, Bristol-Myers Squibb,
- Li, X, Dawant, BM, Welch, EB, Chakravarthy, AB, Freehardt, D, Mayer, I, Kelley, M, Meszoely, I, Gore, JC, Yankeelov, TE A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. Magn Reson Imaging, 2009.
- Cuneo, KC, Geng, L, Fu, A, Orton, D, Hallahan, DE, Chakravarthy, AB SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys, 71(3), 873-9, 2008.
- Yankeelov, TE, Lepage, M, Chakravarthy, A, Broome, EE, Niermann, KJ, Kelley, MC, Meszoely, I, Mayer, IA, Herman, CR, McManus, K, Price, RR, Gore, JC Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 25(1), 1-13, 2007.
- Chakravarthy, AB, Kelley, MC, McLaren, B, Truica, CI, Billheimer, D, Mayer, IA, Grau, AM, Johnson, DH, Simpson, JF, Beauchamp, RD, Jones, C, Pietenpol, JA Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res, 12(5), 1570-6, 2006.
- Choy, H, Chakravarthy, A, Kim, JS Radiation therapy for non-small cell lung cancer (NSCLC). Cancer Treat Res, 105121-48, 2001.
- Hallahan, DE, Qu, S, Geng, L, Cmelak, A, Chakravarthy, A, Martin, W, Scarfone, C, Giorgio, T Radiation-mediated control of drug delivery. Am J Clin Oncol, 24(5), 473-80, 2001.
- Hallahan, DE, Geng, L, Cmelak, AJ, Chakravarthy, AB, Martin, W, Scarfone, C, Gonzalez, A Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature. J Control Release, 74(1-3), 183-91, 2001.
- Chakravarthy, A, Choy H "A Phase I Trial of outpatient Weekly irinotecan/carboplatin and concurrent radiation for Stage III unresectable non-small-cell lung cancer." Vanderbilt-Ingram Cancer Center Affiliate Network Trial, Brief communication, Clinical Lung Cancer , 1(4), 310-311, 2000.
- Chakravarthy, A, Choy, H A phase I trial of outpatient weekly irinotecan/carboplatin and concurrent radiation for stage III unresectable non small-cell lung cancer: a Vanderbilt-Ingram Cancer Center Affiliate Network Trial. Clin Lung Cancer, 1(4), 310-1, 2000.
- Chakravarthy, A, Nicholson B, Kelley M, Beauchamp D, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J "A pilot study of neoadjuvant paclitaxel and radiation therapy with correlative molecular studies in Stage II/III breast cancer." Clinical Breast Cancer , 1(1), 68-71, 2000.
- Chakravarthy, A, Nicholson, B, Kelley, M, Beauchamp, D, Johnson, D, Frexes-Steed, M, Simpson, J, Shyr, Y, Pietenpol, J A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. Clin Breast Cancer, 1(1), 68-71, 2000.
- Choy, H, Chakravarthy, A, Devore, RF, Jagasia, M, Hande, KR, Roberts, JR, Johnson, DH, Yunus, F Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology (Williston Park), 14(7 Suppl 5), 43-6, 2000.
- Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurek ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ "Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy and CA 19-9 levels." Int J Radiat Oncol Biol Phys., 44(5), 151039-46, 1999.
- Choy, H, Chakravarthy, A "Phase I trial of Irinotecan and concurrent radiation therapy for stage III non-small cell lung cancer." Cancer Conference Highlights, 4(6-7), 12, 1999.
- Mignano, J.E., Zahurak, M.L., Chakravarthy, A., Piantadosi, S., Dooley, W.C., Gage,I "Significance of axillary nodal extranodal soft tissue extension and indications for post-mastectomy irradiation." Cancer, 86(7), 1258-62, 1999.
- Chakravarthy, A., Johnson, D., Choy, H "The Role of Radiation with or without Chemotherapy in the management of NSCLC." Oncology, 13: 10 (supp 5)93-100, 1999.
- Chakravarthy, A, Johnson, D, Choy, H The role of radiation, with or without chemotherapy, in the management of NSCLC. Oncology (Williston Park), 13(10 Suppl 5), 93-100, 1999.
- B.S.- The Johns Hopkins University Baltimore, Maryland
- M.D. -George Washington University, Washington, DC
- Resident in Radiation Oncology-The Johns Hopkins Univeristy, Baltimore, Maryland
- Resident in Internal Medicine - Mayo Clinic, Rochester, Minnesota